Ottawa-based CannaRoyalty (CSE:CRZ) (OTCQX: CNNRF) investee, Resolve Digital Health, maker of the Breeze Smart Inhaler, announced an exclusive deal to source cannabis from Aphria (TSX: APHQF), one of Canada’s largest medical cannabis producers. Resolve will package the cannabis in its proprietary Breeze inhalers and market them globally.
Breeze Smart Inhalers provide metered, learned dosing and strain selection appropriate to a patient’s condition, continuously improving efficacy and patient experience.
Resolve will market its Breeze inhalers in Canada the USA and Australia.
On October 11, 2017, Resolve closed a deal giving Liberty Health Sciences exclusive distribution rights to market the inhalers in Florida. In summer 2017, Resolve signed a deal allowing the LeafCann Group to promote Breeze inhalers in Australia.
CannaRoyalty is an active investor and operator in the cannabis industry. It owns 27% of Resolve, worth roughly $7 million. Its stock traded between $1.500 – $3.800 over the last 52 weeks and closed at $2.90 today. Market cap is $122.07m, making it the roughly 50thlargest cannabis company by that measure.
Resolve markets its medical cannabis inhalers for the relief of symptoms from cancer, arthritis, migraines, and chronic pain. The inhalers are currently available in select pharmacies in the USA.
Aphria, with a market cap of $841.80m, is roughly the 7th largest cannabis company. Its stock closed today at $6.06.